2024
OVERTURE Phase 2 Clinical Trial MRI Outcomes Demonstrate Consistent Treatment Benefits in Subgroup Analysis
Kern R, Kuang C, Seshagiri C, Konisky A, Galley A, Boasso A, Hempel E, Malchano Z, Vaughan B, Cimenser A, Da X, Shpokayte M, Hajos M. OVERTURE Phase 2 Clinical Trial MRI Outcomes Demonstrate Consistent Treatment Benefits in Subgroup Analysis. Alzheimer's & Dementia 2024, 20: e085091. PMCID: PMC11714597, DOI: 10.1002/alz.085091.Peer-Reviewed Original ResearchRandomized Controlled TrialsAPOE4 carrier statusBaseline subgroupsMild-moderate Alzheimer's diseasePhase 2 clinical trialIndicators of neurodegenerationBrain atrophyBrain volume outcomesBaseline ageBrain volume lossWhole brain volume lossCarrier statusWBVMagnetic resonance imagingAlzheimer's diseaseBaseline covariatesMonth 6Subgroup analysisAt-homeParticipantsClinical trialsTreatment outcomesActive treatmentOne-hourSham treatmentLong-Term Exposure to Arsenic in Community Water Supplies and Risk of Cardiovascular Disease among Women in the California Teachers Study
Medgyesi D, Bangia K, Spielfogel E, Fisher J, Madrigal J, Jones R, Ward M, Lacey J, Sanchez T. Long-Term Exposure to Arsenic in Community Water Supplies and Risk of Cardiovascular Disease among Women in the California Teachers Study. Environmental Health Perspectives 2024, 132: 107006. PMID: 39440943, PMCID: PMC11498017, DOI: 10.1289/ehp14410.Peer-Reviewed Original ResearchConceptsBody mass indexIschemic heart diseaseHazard ratioCardiovascular diseaseHealth care administrative recordsSmoking statusCalifornia Teachers Study cohortIschemic heart disease casesRisk of ischemic heart diseaseParticipant's residential addressNeighborhood socioeconomic statusCalifornia Teachers StudyCardiovascular disease casesCases of ischemic heart diseaseCardiovascular disease riskRisk of cardiovascular diseaseIncreased cardiovascular disease riskResidential addressesFollow-upSocioeconomic statusYears of ageStratified analysisBaseline ageTeachers StudyCommunity water suppliesProphylaxis with recombinant factor IX Fc fusion protein reduces the risk of bleeding and delays time to first spontaneous bleed event in previously untreated patients with haemophilia B: A post hoc analysis of the PUPs B‐LONG study
Nolan B, Recht M, Rendo P, Falk A, Foster M, Casiano S, Rauch A, Shapiro A. Prophylaxis with recombinant factor IX Fc fusion protein reduces the risk of bleeding and delays time to first spontaneous bleed event in previously untreated patients with haemophilia B: A post hoc analysis of the PUPs B‐LONG study. European Journal Of Haematology 2024, 113: 485-492. PMID: 38922990, DOI: 10.1111/ejh.14252.Peer-Reviewed Original ResearchConceptsRecombinant FIX Fc fusion proteinSpontaneous bleedingRisk of bleedingHemophilia BPost Hoc AnalysisUntreated patientsRecombinant factor IX Fc fusion proteinBaseline ageHoc AnalysisInitial treatment regimensMedian time to eventKaplan-Meier analysisSpontaneous bleeding eventsFc fusion proteinTime to eventProphylaxis typeBleeding eventsTreatment regimenTreatment regimensTreatment patternsTreat ODBleedingProphylaxisFixed replacementSevere casesBlood type as a risk factor for pancreatic ductal adenocarcinoma.
Rahimi Larki N, Skanderson M, Tate J, Levinson R, Hauser R, Brandt C, Yang Y, Justice A, Wang L. Blood type as a risk factor for pancreatic ductal adenocarcinoma. Journal Of Clinical Oncology 2024, 42: 10559-10559. DOI: 10.1200/jco.2024.42.16_suppl.10559.Peer-Reviewed Original ResearchPancreatic ductal adenocarcinoma riskVeterans Health AdministrationRisk of pancreatic ductal adenocarcinomaNon-O blood typeNeighborhood-level socioeconomic dataIntegrated healthcare systemHigh risk of pancreatic ductal adenocarcinomaPancreatic ductal adenocarcinomaAssociated with higher riskAssociated with increased riskUnited StatesHealth AdministrationOutpatient encountersHealthcare systemBaseline ageAlcohol useIndex dateAssociation of blood typeCancer deathWhite populationSocioeconomic dataBlack patientsDiverse populationsRisk factorsBlood typeEstimating risk for pancreatic cancer among 9.4 million veterans in care.
Wang L, Rahimi Larki N, Skanderson M, Tate J, Hauser R, Brandt C, Yang Y, Justice A. Estimating risk for pancreatic cancer among 9.4 million veterans in care. Journal Of Clinical Oncology 2024, 42: 10544-10544. DOI: 10.1200/jco.2024.42.16_suppl.10544.Peer-Reviewed Original ResearchVeterans Health AdministrationGeneral populationAlcohol useIntegrated health systemElectronic health recordsTen-year riskHistory of cancerLoss to follow-upFollow-upEvaluated model discriminationMedian baseline ageCox proportional hazards modelsRisk prediction modelHealth recordsProportional hazards modelHealth systemHealth AdministrationMultivariate Cox proportional hazards modelSmoking statusCharlson Comorbidity IndexBaseline ageClinical reasoningRange of risksHazards modelFinal predictorsDiabetes is associated with increased liver cancer incidence and mortality in adults: A report from Asia Cohort Consortium
Ho N, Abe S, Rahman S, Islam R, Saito E, Gupta P, Pednekar M, Sawada N, Tsugane S, Tamakoshi A, Kimura T, Shu X, Gao Y, Koh W, Cai H, Wen W, Sakata R, Tsuji I, Malekzadeh R, Pourshams A, Kanemura S, Kim J, Chen Y, Ito H, Oze I, Nagata C, Wada K, Sugawara Y, Park S, Shin A, Yuan J, Wang R, Kweon S, Shin M, Poustchi H, Vardanjani H, Ahsan H, Chia K, Matsuo K, Qiao Y, Rothman N, Zheng W, Inoue M, Kang D, Boffetta P. Diabetes is associated with increased liver cancer incidence and mortality in adults: A report from Asia Cohort Consortium. International Journal Of Cancer 2024, 155: 854-870. PMID: 38661292, DOI: 10.1002/ijc.34965.Peer-Reviewed Original ResearchLiver cancer incidenceAsia Cohort ConsortiumBaseline diabetesCancer incidenceCohort ConsortiumAssociated with increased liver cancer riskMortality of liver cancerHazard ratioLiver cancer mortalityTwo-stage meta-analysisLiver cancer riskMeta-analysisCox proportional hazards modelsBody mass indexFollow-up timeProportional hazards modelCancer mortalityCancer riskTobacco smokeBaseline ageCumulative incidence of deathCancer diagnosisCohort studyMeta-analytic approachMass index
2023
Number of completed exercise sessions is associated with slower brain atrophy in MCI over 12 months in the EXERT trial
Digma L, Aslanyan V, Brewer J, Bevins E, Katula J, Chmelo E, Hodge H, LaCroix A, Shadyab A, Jacobs D, Salmon D, Feldman H, Pa J, Baker L. Number of completed exercise sessions is associated with slower brain atrophy in MCI over 12 months in the EXERT trial. Alzheimer's & Dementia 2023, 19 DOI: 10.1002/alz.079285.Peer-Reviewed Original ResearchSupervised exercise sessionsBrain atrophyExercise sessionsAlzheimer's Disease Cooperative StudyLess brain atrophySupervised exercise interventionLower dementia riskLate-life exerciseAmount of exerciseInferior lateral ventricleExercise armExercise interventionDementia riskBaseline ageCDR-SBAerobic trainingLateral ventricleHigh adherenceIntervention adherenceNumber of sessionsVentricular expansionExercise typePlasma Aβ42/40Amnestic MCICognitive declineAge at Menopause and the Risk of Stroke: Observational and Mendelian Randomization Analysis in 204 244 Postmenopausal Women
Tschiderer L, Peters S, van der Schouw Y, van Westing A, Tong T, Willeit P, Seekircher L, Moreno‐Iribas C, Huerta J, Crous‐Bou M, Söderholm M, Schulze M, Johansson C, Själander S, Heath A, Macciotta A, Dahm C, Ibsen D, Pala V, Mellemkjær L, Burgess S, Wood A, Kaaks R, Katzke V, Amiano P, Rodriguez‐Barranco M, Engström G, Weiderpass E, Tjønneland A, Halkjær J, Panico S, Danesh J, Butterworth A, Onland‐Moret N. Age at Menopause and the Risk of Stroke: Observational and Mendelian Randomization Analysis in 204 244 Postmenopausal Women. Journal Of The American Heart Association 2023, 12: e030280. PMID: 37681566, PMCID: PMC10547274, DOI: 10.1161/jaha.123.030280.Peer-Reviewed Original ResearchConceptsMendelian randomization analysisRisk of strokeStatistically significant associationRandomization analysisSignificant associationHistory of strokeEPIC-CVDPooled mean ageHigh risk of strokeUK BiobankYears younger ageBaseline ageHazard ratioStroke subtypesObservational studyPooled hazard ratioHemorrhagic strokeEarly menopauseYounger ageMean ageHigh riskMedian Follow-UpStrokeRegression analysisWomen
2022
Depressive Multimorbidity and Trajectories of Functional Status among Older Americans: Differences by Racial/Ethnic Group
Botoseneanu A, Elman M, Allore H, Dorr D, Newsom J, Nagel C, Quiñones A. Depressive Multimorbidity and Trajectories of Functional Status among Older Americans: Differences by Racial/Ethnic Group. Journal Of The American Medical Directors Association 2022, 24: 250-257.e3. PMID: 36535384, PMCID: PMC10280885, DOI: 10.1016/j.jamda.2022.11.015.Peer-Reviewed Original ResearchConceptsFunctional limitationsOlder adultsSomatic multimorbidityBody mass indexScreening/treatmentDaily living limitationsUS older adultsNon-Hispanic blacksHigher depressive symptomsAdults age 65Race/ethnicityMass indexTreatment optionsBaseline ageFunctional statusRepresentative sampleHigh prevalenceInstrumental activitiesFunctional declineDaily livingMultimorbidityDepressive symptomsSomatic diseasesDepressive symptomatologyEthnic groupsAbstract 12593: Type 2 Diabetes Mellitus Polygenic Score Predicts New Onset Diabetes in Patients With Established Atherosclerotic Cardiovascular Disease: A FOURIER Sub-Study
Moura F, Kamanu F, Wiviott S, Giugliano R, Florez J, Roselli C, Keech A, Lubitz S, Ellinor P, Ruff C, Marston N, Sabatine M. Abstract 12593: Type 2 Diabetes Mellitus Polygenic Score Predicts New Onset Diabetes in Patients With Established Atherosclerotic Cardiovascular Disease: A FOURIER Sub-Study. Circulation 2022, 146: a12593-a12593. DOI: 10.1161/circ.146.suppl_1.12593.Peer-Reviewed Original ResearchNew-onset T2DPolygenic scoresGenetic riskClinical risk factorsAtherosclerotic cardiovascular diseaseGenome-wide significant single nucleotide polymorphismsGenetic risk categoriesAmerican Diabetes Association definitionRisk factorsCardiovascular diseaseSignificant single nucleotide polymorphismsPredicting new-onset diabetesBMI levelsNew-onset diabetes casesAssociation definitionType 2 diabetesNormal weightBaseline ageDiabetes casesNew-onset diabetesPre-diabetesSub-studySingle nucleotide polymorphismsBMIT2D
2021
Bariatric-Metabolic Surgery Utilisation in Patients With and Without Diabetes: Data from the IFSO Global Registry 2015–2018
Welbourn R, Hollyman M, Kinsman R, Dixon J, Cohen R, Morton J, Ghaferi A, Higa K, Ottosson J, Pattou F, Al-Sabah S, Anvari M, Himpens J, Liem R, Våge V, Walton P, Brown W, Kow L. Bariatric-Metabolic Surgery Utilisation in Patients With and Without Diabetes: Data from the IFSO Global Registry 2015–2018. Obesity Surgery 2021, 31: 2391-2400. PMID: 33638756, PMCID: PMC8113173, DOI: 10.1007/s11695-021-05280-6.Peer-Reviewed Original ResearchConceptsBody mass indexType 2 diabetes mellitusMethodsCross-sectional analysisRates of T2DMBariatric-metabolic surgeryHigh rateGastric bypassPrimary surgerySleeve gastrectomyDiabetes mellitusMass indexGlobal RegistryBaseline ageNational registryInclusion criteriaT2DMType of operationPatientsOlder menWomenSurgeryRegistryMenHigher proportionCommon operationEvaluating the Success of Perioperative Self-Guided Meditation in Reducing Sleep Disturbance After Total Knee Arthroplasty
Canfield MJ, Cremins MS, Vellanky SS, Teng R, Belniak RM. Evaluating the Success of Perioperative Self-Guided Meditation in Reducing Sleep Disturbance After Total Knee Arthroplasty. The Journal Of Arthroplasty 2021, 36: s215-s220.e2. PMID: 33663887, DOI: 10.1016/j.arth.2021.01.070.Peer-Reviewed Original ResearchConceptsTotal knee arthroplastyPerioperative periodSleep qualityKnee arthroplastySleep disturbancesPatient-reported outcome measuresDecreased pain toleranceSignificant differencesVideo groupTKA recoveryTKA patientsVeterans RANDNonpharmacologic interventionsKnee injuriesSingle institutionBaseline ageHealth SurveyOutcome measuresFrequent complaintSleep awakeningsNonvideo groupPain tolerancePatientsSatisfaction scoresOutcome variables
2020
Impact of adjuvant chemotherapy or tamoxifen-alone on the ovarian reserve of young women with breast cancer
Goldfarb S, Turan V, Bedoschi G, Taylan E, Abdo N, Cigler T, Bang H, Patil S, Dickler M, Oktay K. Impact of adjuvant chemotherapy or tamoxifen-alone on the ovarian reserve of young women with breast cancer. Breast Cancer Research And Treatment 2020, 185: 165-173. PMID: 32930927, PMCID: PMC7877450, DOI: 10.1007/s10549-020-05933-7.Peer-Reviewed Original ResearchConceptsAnti-Mullerian hormoneOvarian reserveAdjuvant chemotherapyBreast cancerAMH levelsChemotherapy regimensCompletion of ACSerum AMH levelsAdjuvant tamoxifenAMH recoveryChemotherapy groupPrimary diagnosisBaseline ageMethodsOne hundredAMH assessmentRegimensChemotherapyYoung womenTamoxifenSignificant recoveryCancerMixed effects modelsMonthsTreatment effectsWomenThe effect of neighborhood social environment on prostate cancer development in black and white men at high risk for prostate cancer
Lynch S, Handorf E, Sorice K, Blackman E, Bealin L, Giri V, Obeid E, Ragin C, Daly M. The effect of neighborhood social environment on prostate cancer development in black and white men at high risk for prostate cancer. PLOS ONE 2020, 15: e0237332. PMID: 32790761, PMCID: PMC7425919, DOI: 10.1371/journal.pone.0237332.Peer-Reviewed Original ResearchConceptsProstate-specific antigenPCa family historyHigh-risk menProbability of PCaFamily historyPCa diagnosisRisk menWhite menDigital rectal examEarly Detection ProgramClinical risk assessmentProstate cancer disparitiesProstate cancer developmentPatient risk assessmentNeighborhood socioeconomic factorsPatient-level modelsCox regressionRectal examBaseline ageCancer disparitiesPatient variablesProstate cancerHigh riskNeighborhood social environmentClinical relevance
2017
Multimorbidity Among Persons Living with Human Immunodeficiency Virus in the United States
Wong C, Gange SJ, Moore RD, Justice AC, Buchacz K, Abraham AG, Rebeiro PF, Koethe JR, Martin JN, Horberg MA, Boyd CM, Kitahata MM, Crane HM, Gebo KA, Gill MJ, Silverberg MJ, Palella FJ, Patel P, Samji H, Thorne J, Rabkin CS, Mayor A, Althoff KN, Freeman A, Cescon A, Rachlis A, Rogers B, Rodriguez B, Grasso C, Benson C, Drozd D, Fiellin D, Haas D, Kirk G, Willig J, Globerman J, Brooks J, Eron J, Montaner J, Gabler K, Anastos K, Mayer K, Jacobson L, Kopansky-Giles M, Klein M, Turner M, Mugavero M, Saag M, Harrigan P, Dubrow R, Hunter-Mellado R, Hogg R, Bosch R, McKaig R, Bebawy S, Rourke S, Napravnik S, Boswell S, Sterling T. Multimorbidity Among Persons Living with Human Immunodeficiency Virus in the United States. Clinical Infectious Diseases 2017, 66: 1230-1238. PMID: 29149237, PMCID: PMC5889007, DOI: 10.1093/cid/cix998.Peer-Reviewed Original ResearchMeSH KeywordsAdultAge FactorsBlack PeopleCohort StudiesDiabetes Mellitus, Type 2FemaleHeterosexualityHIVHIV InfectionsHomosexuality, MaleHumansHypercholesterolemiaHypertensionLongitudinal StudiesMaleMiddle AgedMultimorbidityRenal Insufficiency, ChronicSexual and Gender MinoritiesUnited StatesWhite PeopleConceptsHuman immunodeficiency virusAdjusted prevalence ratiosAge-associated conditionsImmunodeficiency virusMultimorbidity prevalenceClinical careNorth American AIDS Cohort CollaborationEnd-stage liver diseaseMedian baseline ageHIV outpatient clinicChronic kidney diseaseRobust error varianceConfidence intervalsComplex healthcare needsDemographic subgroupsCohort CollaborationComorbidity preventionCohort studyDiabetes mellitusLiver diseaseOutpatient clinicKidney diseasePrevalence ratiosBaseline ageCare complexityPersonality predicts mortality risk: An integrative data analysis of 15 international longitudinal studies
Graham E, Rutsohn J, Turiano N, Bendayan R, Batterham P, Gerstorf D, Katz M, Reynolds C, Sharp E, Yoneda T, Bastarache E, Elleman L, Zelinski E, Johansson B, Kuh D, Barnes L, Bennett D, Deeg D, Lipton R, Pedersen N, Piccinin A, Spiro A, Muniz-Terrera G, Willis S, Schaie K, Roan C, Herd P, Hofer S, Mroczek D. Personality predicts mortality risk: An integrative data analysis of 15 international longitudinal studies. Journal Of Research In Personality 2017, 70: 174-186. PMID: 29230075, PMCID: PMC5722274, DOI: 10.1016/j.jrp.2017.07.005.Peer-Reviewed Original ResearchPattern of protective effectsLow conscientiousnessHigh neuroticismIntegrative data analysisPersonality traitsOlder baseline ageInternational longitudinal studyExtraversionNeuroticismLongitudinal studyPredictor of mortality riskBaseline ageU.S. studiesPersonsMortality riskAgreeablenessConscientiousnessPredictorsPredictors of mortalityParticipantsTraitsSmokingProtective effectAgeStudyThe association between tau PET and retrospective cortical thinning in clinically normal elderly
LaPoint M, Chhatwal J, Sepulcre J, Johnson K, Sperling R, Schultz A. The association between tau PET and retrospective cortical thinning in clinically normal elderly. NeuroImage 2017, 157: 612-622. PMID: 28545932, PMCID: PMC5772972, DOI: 10.1016/j.neuroimage.2017.05.049.Peer-Reviewed Original ResearchConceptsTemporal regionsCortical thinningCortical ROIsCortical thicknessRetrospective longitudinal analysisRight temporal regionAssociated with neuronal lossBaseline ageNormal cohortNeuronal lossRate of cortical thinningLeft cuneusPathologyMedial temporal regionsVolumetric ROIsReference regionAtrophyThick cross-sectionsCortical regionsBilateral parahippocampal cortexLongitudinal atrophyLongitudinal analysisLeft superior temporal sulcusCortexBrain studiesAssociation of weight change with telotristat ethyl in the treatment of carcinoid syndrome.
Weickert M, Kaltsas G, Hörsch D, Lapuerta P, Pavel M, Valle J, Caplin M, Bergsland E, Kunz P, Anthony L, Grande E, Oberg K, Warner R, Lombard-Bohas C, Welin S, Fleming R, Kittur A, Arnold K, Yang Q, Kulke M. Association of weight change with telotristat ethyl in the treatment of carcinoid syndrome. Journal Of Clinical Oncology 2017, 35: e15692-e15692. DOI: 10.1200/jco.2017.35.15_suppl.e15692.Peer-Reviewed Original ResearchMetastatic neuroendocrine tumorsCarcinoid syndromeWeek 12Neuroendocrine tumorsTelotristat ethylWeight gainWeight lossWeight changeDouble-blind treatment periodUncontrolled carcinoid syndromeBowel movement frequencyBody mass indexCochrane-Armitage testStatistical analysis planBM frequencyAdverse eventsAnalogue therapyDiarrhea severityPerformance statusMass indexBaseline ageTreatment periodPatientsReduced survivalIncidence
2016
LBPS 02-52 EFFECT OF EMPAGLIFLOZIN ON HEART FAILURE OUTCOMES IN SUBGROUPS BY AGE
Lee D, Monteiro P, Clark D, Hantel S, Woerle H, Inzucchi S, Fitchett D. LBPS 02-52 EFFECT OF EMPAGLIFLOZIN ON HEART FAILURE OUTCOMES IN SUBGROUPS BY AGE. Journal Of Hypertension 2016, 34: e520. DOI: 10.1097/01.hjh.0000501423.64635.bd.Peer-Reviewed Original ResearchHeart failure hospitalizationHigh cardiovascular riskCardiovascular deathFailure hospitalizationHeart failureStandard of careType 2 diabetesEmpagliflozin groupCardiovascular riskMajor adverse cardiovascular eventsEMPA-REG OUTCOME trialEMPA-REG OUTCOMEAdverse cardiovascular eventsEffect of empagliflozinHeart failure outcomesMedian observation timeRisk of hospitalizationCardiovascular eventsPlacebo groupAdverse eventsEffect of ageOutcome trialsSafety profileMean ageBaseline ageSurvival Advantage Mechanism: Inflammation as a Mediator of Positive Self-Perceptions of Aging on Longevity
Levy BR, Bavishi A. Survival Advantage Mechanism: Inflammation as a Mediator of Positive Self-Perceptions of Aging on Longevity. The Journals Of Gerontology Series B 2016, 73: 409-412. PMID: 27032428, PMCID: PMC5927092, DOI: 10.1093/geronb/gbw035.Peer-Reviewed Original Research
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply